DK0826695T3 - Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer - Google Patents

Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer

Info

Publication number
DK0826695T3
DK0826695T3 DK97115188T DK97115188T DK0826695T3 DK 0826695 T3 DK0826695 T3 DK 0826695T3 DK 97115188 T DK97115188 T DK 97115188T DK 97115188 T DK97115188 T DK 97115188T DK 0826695 T3 DK0826695 T3 DK 0826695T3
Authority
DK
Denmark
Prior art keywords
stem cell
destruction
tumor cells
bispecific antibodies
cell grafts
Prior art date
Application number
DK97115188T
Other languages
English (en)
Inventor
Horst Dr Lindhofer
Helge Dr Menzel
Hans-Jochem Prof Dr Kolb
Stefan Prof Dr Thierfelder
Original Assignee
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19649223A external-priority patent/DE19649223C2/de
Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt
Application granted granted Critical
Publication of DK0826695T3 publication Critical patent/DK0826695T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DK97115188T 1996-09-03 1997-09-02 Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer DK0826695T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19635743 1996-09-03
DE19649223A DE19649223C2 (de) 1996-09-03 1996-11-27 Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern

Publications (1)

Publication Number Publication Date
DK0826695T3 true DK0826695T3 (da) 2002-04-15

Family

ID=26028996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97115188T DK0826695T3 (da) 1996-09-03 1997-09-02 Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer

Country Status (6)

Country Link
US (2) US5985276A (da)
EP (1) EP0826695B1 (da)
JP (1) JP3257970B2 (da)
AT (1) ATE210682T1 (da)
DK (1) DK0826695T3 (da)
ES (1) ES2169299T3 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169299T3 (es) * 1996-09-03 2002-07-01 Gsf Forschungszentrum Umwelt Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6994853B1 (en) 1998-09-25 2006-02-07 Trion Pharma Gmbh Time-staggered utilization of tumor cells in combination with intact antibodies for immunization
US6319675B1 (en) 1999-11-24 2001-11-20 Millennium Pharmaceuticals, Inc. Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
US7208152B2 (en) * 1999-11-24 2007-04-24 Millennium Pharmaceuticals, Inc. Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
WO2003011337A1 (en) * 2001-07-30 2003-02-13 Keio University MEDICINAL COMPOSITIONS CONTAINING Fc RECEPTOR Ϝ-CHAIN ACTIVATOR
ES2624547T3 (es) 2001-11-14 2017-07-14 Janssen Biotech, Inc. Anticuerpos anti il 6, composiciones, métodos y usos
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2005077065A2 (en) * 2004-02-09 2005-08-25 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
US8066989B2 (en) * 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
EP1874821B1 (de) 2005-04-26 2013-04-17 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
WO2007062466A1 (en) * 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
WO2007134274A2 (en) * 2006-05-12 2007-11-22 Attenuon, Llc Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy
CA2670315A1 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of California Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
JP5623384B2 (ja) 2008-04-21 2014-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 選択的高親和性リガンドおよびこれらを作製する方法
PT2975051T (pt) 2009-06-26 2021-05-04 Regeneron Pharma Anticorpos biespecíficos rapidamente isolados com formato de imunoglobulina nativa
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
JP5887337B2 (ja) 2010-03-30 2016-03-16 ヤンセン バイオテツク，インコーポレーテツド ヒト化ｉｌ−２５抗体
CA2801210C (en) 2010-06-19 2020-07-21 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
TWI807362B (zh) * 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
EP2578230A1 (en) 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
ES2920677T3 (es) 2013-12-24 2022-08-08 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-VISTA
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
CA3014013A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
MX2019003703A (es) 2016-09-30 2020-08-13 Janssen Biotech Inc Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
US11208474B2 (en) 2016-11-16 2021-12-28 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL23 specific antibody
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
IL310216A (en) 2018-03-05 2024-03-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
SG11202012706PA (en) 2018-06-21 2021-01-28 Yumanity Therapeutics Inc Compositions and methods for the treatment and prevention of neurological disorders
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP3976183A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
KR20230156764A (ko) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체에 의해 tnf 요법에 부적절한 반응을 보이는 건선성 관절염 환자를 치료하는 방법
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US5320942A (en) * 1987-02-19 1994-06-14 Vito Quaranta Method of diagnosing the presence of abnormal epithelial tissue using monoclonal antibodies to the A6 B4 cell surface protein
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
ES2169299T3 (es) * 1996-09-03 2002-07-01 Gsf Forschungszentrum Umwelt Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.

Also Published As

Publication number Publication date
US5985276A (en) 1999-11-16
JPH10179151A (ja) 1998-07-07
JP3257970B2 (ja) 2002-02-18
ATE210682T1 (de) 2001-12-15
US6210668B1 (en) 2001-04-03
EP0826695A1 (de) 1998-03-04
EP0826695B1 (de) 2001-12-12
ES2169299T3 (es) 2002-07-01

Similar Documents

Publication Publication Date Title
DK0826695T3 (da) Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
ATE196607T1 (de) Verfahren zur ex vivo-immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer antikörper
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
DK0826696T3 (da) Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
EP1016867A4 (en) IMMUNOASSAY FOR DETERMINING BNP
DE69638355D1 (de) Anti-CD3-Antikörper zur Verwendung zur Induzierung von Immunsuppression
DK1194167T3 (da) Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
WO1994016094A3 (en) Recombinant anti-vla4 antibody molecules
AU6054398A (en) Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
DK0752869T3 (da) Celler med talrige ændrede epitoper på et overfladeantigen til anvendelse ved transplantationen
ES2150573T3 (es) Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
FI832897A0 (fi) Bispecifika antikroppdeterminanter
DK0525034T3 (da) Antigen/anti-antigenspaltning
DE60033455D1 (de) Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie
EP0787743A3 (de) A3C6E2, ein monoklonaler Antikörper spezifisch für den humanen Stammzellfaktor (SCF)-Rezeptor
GR3031607T3 (en) Selective system scan for multizone radiotelephone subscriber units.
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
ATE80467T1 (de) Immuntestverfahren.
DK329789D0 (da) Monoklonalt antistof
DE59710330D1 (de) Hybridzelle und deren Verwendung zur Herstellung eines Arzneimittels zur Induktion einer Tumorimmunität
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
NO861554L (no) Anti-urokinasemonoklonalt antistoff, matrise inneholdende dette, testmetode og biokjemisk testutstyr som anvender det.
DK98692A (da) Monoklonalt antistof og fremgangsmaade til fremstilling deraf, hybridoma, som producerer det monoklonale antistof, og proeve for tumorcellefoelsomhed under anvendelse af det monoklonale antistof